IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishThe proportion of patients with cancers who develop invasive fungal infections has increased dramatically over the past few decades. Most of these infections are diagnosed in patients with hematological malignancies, mainly in patients with acute myeloid leukemia and those undergoing allogeneic hematopoietic stem cell transplantation. For years deoxycolate amphotericin B has been considered the drug of choice for the treatment of invasive aspergillosis, but it has been outclassed by its lipid formulations and new triazoles (i.e. voriconazole), that produced better response rates; nonetheless recovery from neutropenia remains the most important factor influencing outcome.
Pagano, L., Valentini, C., Fianchi, L., Caira, M., Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?, <<JOURNAL OF CHEMOTHERAPY>>, 2011; 23 (1): 5-8 [http://hdl.handle.net/10807/1372]
| Autori: | ||
| Titolo: | Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? | |
| Data di pubblicazione: | 2011 | |
| Abstract: | The proportion of patients with cancers who develop
invasive fungal infections has increased dramatically over
the past few decades. Most of these infections are diagnosed
in patients with hematological malignancies, mainly
in patients with acute myeloid leukemia and those undergoing
allogeneic hematopoietic stem cell transplantation.
For years deoxycolate amphotericin B has been considered
the drug of choice for the treatment of invasive aspergillosis,
but it has been outclassed by its lipid formulations
and new triazoles (i.e. voriconazole), that produced
better response rates; nonetheless recovery from neutropenia
remains the most important factor influencing
outcome. The proportion of patients with cancers who develop invasive fungal infections has increased dramatically over the past few decades. Most of these infections are diagnosed in patients with hematological malignancies, mainly in patients with acute myeloid leukemia and those undergoing allogeneic hematopoietic stem cell transplantation. For years deoxycolate amphotericin B has been considered the drug of choice for the treatment of invasive aspergillosis, but it has been outclassed by its lipid formulations and new triazoles (i.e. voriconazole), that produced better response rates; nonetheless recovery from neutropenia remains the most important factor influencing outcome. | |
| Lingua: | Inglese | |
| Rivista: | ||
| Citazione: | Pagano, L., Valentini, C., Fianchi, L., Caira, M., Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?, <<JOURNAL OF CHEMOTHERAPY>>, 2011; 23 (1): 5-8 [http://hdl.handle.net/10807/1372] | |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
Copyright © 2022